The condition most men don't know they have
Osteoporosis causes bones to become thin and brittle over time. It raises the risk of serious fractures — especially in the spine, hip, and wrist. A broken hip in an older man can be life-altering, and recovery is often harder than people expect.
About one in five men over age 50 will have an osteoporosis-related fracture in their lifetime. Despite that, men are far less likely to be tested or treated than women. When treatment does happen, doctors have had little data to guide which drug to choose.
Two families of drugs — but which is better?
There are two main approaches to treating osteoporosis.
The first is antiresorptive drugs — medications like alendronate (Fosamax), risedronate, zoledronic acid (Reclast), and denosumab (Prolia). Think of your skeleton like a house under constant renovation. A crew is always tearing down old bone while another builds new bone. Antiresorptive drugs slow down the demolition crew, giving your body a chance to catch up.
The second is anabolic drugs — medications like teriparatide (Forteo) and abaloparatide (Tymlos). These work differently. Instead of just hitting the brakes on breakdown, they actively signal your body to build fresh bone. More like calling in extra construction workers.
Both types are approved for use in men. But until now, no one had done a thorough, side-by-side comparison across all the available trials.
What the study actually looked at
Researchers conducted what's called a Bayesian network meta-analysis — a method that combines data from many separate studies to compare treatments even when those treatments were never tested head-to-head in the same trial.
They pulled together 18 randomized controlled trials (the gold standard of medical research) published through 2025. The trials ranged from 19 to 1,199 participants each and tested six medications in total. The main thing researchers measured was how much each drug changed bone mineral density (BMD) — a measure of bone strength — after 12 months of treatment.
They looked at three locations: the lumbar spine (lower back), the femoral neck (top of the thigh bone), and the total hip.
The results that stand out
Here's where things get interesting.
When researchers compared the two drug classes directly, anabolic drugs came out ahead in two of the three measurement sites. At the lumbar spine, anabolic drugs were associated with roughly twice the bone density improvement compared to antiresorptive drugs. At the total hip, anabolic drugs also showed a stronger effect.
The femoral neck — a critical fracture site — was the one area where antiresorptive drugs showed a modest edge.
Both drug classes had similar rates of side effects and serious adverse events. Safety was not meaningfully different between them.
At the individual drug level, abaloparatide and teriparatide ranked highest for spine and hip gains. Alendronate performed particularly well at the femoral neck and had a favorable safety profile among antiresorptive options.
This doesn't mean every man needs the more powerful drug
Anabolic drugs tend to be more expensive. They are usually given as daily or weekly injections, not as a simple pill. Most guidelines currently reserve them for patients at the highest risk of fractures — not every man with low bone density.
This study does not change that calculus on its own. What it does is give doctors better evidence to weigh when a man does need treatment. If improving spine and hip density is the priority, the data now more clearly point toward anabolic agents — assuming other factors like cost, access, and patient preference align.
Where the evidence has gaps
This analysis has real strengths, but also limits worth knowing.
The 18 trials varied widely in size — some were quite small, with fewer than 50 participants. Not every drug was tested against every other drug directly, which means some comparisons are indirect and carry more uncertainty. Study designs and follow-up periods also differed across trials.
In other words, the findings offer useful guidance, but they cannot predict exactly what will happen for any one man in any one clinic. Individual factors always matter.
What happens next
This research provides the first comprehensive, evidence-based map of treatment options specifically for men with osteoporosis. The authors hope it prompts broader screening, earlier conversations between men and their doctors, and more personalized treatment decisions.
Future trials could make these comparisons even sharper — particularly with longer follow-up periods and more consistent measurement methods. For now, men with osteoporosis and their doctors have more evidence than ever to work with.
